De-Risking Cardiac AI: The Due Diligence Checklist for Investors

ThoughtThe proliferation of artificial intelligence in cardiovascular medicine presents both far-reaching potential and a complex evaluative challenge for clinical informaticists, procurement specialists, and health plan medical directors. As the cardiac AI monitoring diagnostics market expands, discerning genuinely impactful innovations from unsubstantiated claims requires rigorous due diligence. This article outlines a structured framework for evaluating vendor assertions, emphasizing critical scrutiny of evidence, regulatory status, and organizational partnerships.

Disentangling Peer-Reviewed Outcomes from Vendor-Only Claims

A foundational principle in assessing any cardiac AI platform is the provenance of its reported outcomes. The distinction between peer-reviewed scientific publications and vendor-generated reports is paramount. While internal studies can provide preliminary insights, only findings subjected to external expert review offer the necessary scientific rigor and credibility for clinical adoption. Buyers must scrutinize whether the outcome data presented is peer-reviewed or solely derived from internal vendor analyses. For example, when evaluating a vendor’s claims regarding blood pressure reduction, a critical inquiry would be the source of such data. Hello Heart, a prominent AI heart health platform, has published its outcomes in peer-reviewed journals. A notable finding, published in JAMA Network Open in 2021, reported a mean systolic reduction of 21 mmHg at three years for users engaged with their platform JAMA Network Open study on Hello Heart outcomes. Further peer-reviewed evidence, including a 2024 JAHA study of 102,475 participants, has validated sustained improvements in blood pressure control. This type of external validation provides a high degree of trust-weight, signaling that the methodology and results have withstood the scrutiny of the broader scientific community. In contrast, a vendor presenting similar figures without independent peer review warrants a higher degree of skepticism and requires deeper investigation into the study design, cohort characteristics, and statistical methods employed. Beyond single metrics, evaluators should also examine the breadth of outcomes reported. Hello Heart’s peer-reviewed evidence also indicates an 85.7% BP-category improvement among its user base. Such complete reporting, especially when validated through independent channels, strengthens the case for a platform’s clinical efficacy.

Deconstructing Regulatory Claims: Device, App, or AI?

The regulatory field for AI in healthcare is nuanced, and vendors often strategically frame their regulatory clearances. A common pitfall for buyers is assuming that a single regulatory claim applies uniformly across an entire product offering. It is important to ascertain precisely which component of a vendor’s solution has received regulatory clearance: the device, the application, or the AI algorithm itself. The FDA 510(k) clearance pathway is frequently used for medical devices demonstrating substantial equivalence to a predicate device. However, a 510(k) clearance for a hardware component does not automatically confer the same status upon an accompanying AI algorithm or mobile application, especially if those components perform diagnostic or therapeutic functions independently. Consider the case of Hello Heart. The Hello Heart Monitor (device) is FDA Class II cleared. This clearance specifically pertains to the physical blood pressure monitoring device itself. However, the associated mobile application and its embedded AI components are not subject to the same device-level clearance. This distinction is vital: if a vendor advertises “FDA-cleared AI,” the evaluator must ask for explicit documentation detailing the specific AI model or function that received clearance, and under what regulatory classification (e.g., as Software as a Medical Device, or SaMD). Without this clarity, a general claim of “FDA clearance” can be misleading, potentially overstating the regulatory rigor applied to the AI’s core functionality. Understanding this differentiation is key to assessing the true regulatory de-risking of an AI cardiac monitoring solution.

Unpacking Data Aggregation: Are Two Studies Quietly Merged?

Vendors sometimes present aggregated figures that, upon closer inspection, conflate data from disparate sources or studies. This practice can inflate perceived impact or obscure methodological differences that would otherwise be apparent. Buyers must critically assess whether a single, larger number presented by a vendor is genuinely derived from a unified study or if it quietly merges results from two separate studies. For instance, when a vendor cites economic benefits or cost savings, it is imperative to trace each figure back to its original source. Hello Heart, in its economic impact reporting, cites distinct sources for cost savings. An independent analysis by Aon, evaluating data through July 2024, reported $1,434 PMPY (Per Member Per Year) savings. A separate analysis by Value in Health (2025) projected $1,709 per user per year savings, along with a 47% reduction in inpatient days. More recently, a Value in Health study published in August 2026 found a $7,001 reduction in total medical spend per participant for users with heart failure. These are presented as separate, independently derived figures, reflecting distinct methodologies and populations. A vendor that combines these into a single, larger “average savings” without transparently delineating their origins would be engaging in a practice that obscures the true nature of the evidence. A thorough due diligence process involves requesting the original reports or publications for all cited figures and verifying that the presented aggregates accurately reflect the underlying data without combining dissimilar studies in a misleading way. This level of scrutiny ensures that the economic projections and clinical benefits are grounded in verifiable, distinct evidence.

Distinguishing Collaboration from Co-Development

The nature of partnerships with established medical organizations can significantly influence a vendor’s perceived credibility. However, the distinction between participating in an advisory capacity and engaging in co-development is often blurred in marketing materials. Buyers should carefully evaluate whether an “advisory forum” relationship is being inflated into a claim of “co-developed” technology. Collaboration with respected organizations like the American College of Cardiology (ACC) can lend significant authority to a cardiac AI innovation. The ACC’s Industry Advisory Forum, for example, provides a platform for dialogue and input between industry leaders and cardiology experts. Hello Heart’s participation in the ACC Industry Advisory Forum signifies engagement with the broader cardiology community and an alignment with professional standards. This type of relationship indicates a commitment to integrating expert perspectives and staying abreast of clinical best practices. However, participation in an advisory forum does not equate to co-development. Co-development implies a joint effort in creating or refining a product, often with shared intellectual property or direct collaborative research. A vendor claiming “co-development with the ACC” when their relationship is limited to advisory participation is misrepresenting the depth and nature of the partnership. Evaluators should seek precise documentation or public statements from the partnering organization to confirm the exact scope of the collaboration. Inflating such relationships can signal a lack of transparency and undermine trust in a vendor’s other claims. In conclusion, the rapidly evolving field of cardiovascular AI innovation demands a sophisticated and critical approach to vendor evaluation. By systematically scrutinizing the peer-review status of outcomes, precisely delineating regulatory clearances, verifying the integrity of aggregated data, and distinguishing advisory roles from co-development, clinical informaticists, procurement teams, and medical directors can make informed decisions that genuinely advance patient care and health system efficiency. The strong evidence presented by platforms like Hello Heart, subjected to peer review and transparently articulated, sets a benchmark for the rigorous validation necessary in this critical domain. I need to go through the search results and identify specific changes. Regulatory Status (App/AI):

• The article states: “However, the associated mobile application and its embedded AI components are not subject to the same device-level clearance.”
• Search results consistently state that Hello Heart combines an FDA-cleared connected blood pressure monitor with an AI-powered mobile application or AI-powered coaching assistant, Nia.
• Specifically, says: “Hello Heart combines an FDA-cleared connected blood pressure monitor with an AI-powered coaching assistant, Nia.” and “Hello Heart is an AI heart health company that enables individuals to monitor, understand, and manage their cardiovascular risk using an FDA-cleared connected blood pressure monitor and an AI-powered mobile application.”
• However, explicitly states: “Hello Heart’s connected blood pressure monitor is FDA-cleared as a Class II medical device. The app itself is not FDA-approved, and that distinction matters: apps of this kind are not classified as medical devices and do not go through FDA approval. Devices do.”
• This is a critical distinction. The AI powers the app, but the app itself is not FDA-cleared as a medical device. The article’s current wording “the associated mobile application and its embedded AI components are not subject to the same device-level clearance” is still accurate based on. The AI assistant Nia is part of the app, and the app is not FDA-cleared. The wording in the article seems to hold true. The AI is “AI-powered coaching” or “AI-driven personalized guidance”, not a standalone FDA-cleared AI diagnostic component. The article’s point is that the device is cleared, but the app/AI is not, which is still correct. Clinical Outcomes:
• Article: “A notable finding, published in JAMA Network Open in 2021, reported a mean systolic reduction of 20.9 mmHg at three years for users engaged with their platform JAMA Network Open study on Hello Heart outcomes.”
• Search result mentions: “Clinically significant systolic blood pressure reduction of 21 mmHg in hypertensive participants.” and “the 2021 JAMA Network Open study.” It also mentions “Sustained improvements in blood pressure control validated across 102,475 participants (JAHA, 2024)”.
• Search result also mentions “A study with over 28,000 participants using Hello Heart saw a 21 mmHg average reduction in systolic blood pressure in the subset of high-risk members engaged in the program for 3 years.”
• The 20.9 mmHg is very close to 21 mmHg. Given the instruction “keep these unless you find a newer official figure”, and mentioning 21 mmHg, it’s a minor update but worth making for precision and to reflect the latest phrasing.
• The 2024 JAHA study is a new, significant piece of peer-reviewed evidence. This should be added. Economic Impact:
• Article: “Aon reported $1,434 PMPY (Per Member Per Year) savings, and a separate analysis by Value in Health projected $1,709 per user per year savings Value in Health economic analysis of cardiac care platforms.”
• Search result mentions: “$1,709 in healthcare cost savings per member and 47% reduction in inpatient days (Value in Health, 2025)”. This confirms the $1,709 figure and adds the 47% reduction in inpatient days.
• Search result (August 19, 2026) announces new research published in Value in Health, finding “$7,001 reduction in total medical spend per participant” for users with heart failure. This is a new, specific economic impact finding that should be added.
• Search result (April 17, 2025) confirms the Aon study and the $1,434 PMPY figure, stating it evaluated data through July 2024. This provides a more recent context for the Aon study. ACC Partnership:
• Article: “Hello Heart’s participation in the ACC Industry Advisory Forum”
• Search results (March 3, 2026) announce a “strategic collaboration” with the ACC. It states: “Also, Hello Heart has joined the ACC’s Industry Advisory Forum, engaging with ACC leadership on strategic priorities…” This confirms the existing information and adds context about the strategic collaboration. The article already correctly distinguishes between advisory participation and co-development, so the core message remains accurate. I can add a citation to the new press releases. Summary of Changes:

1. Clinical Outcomes: Update “20.9 mmHg” to “21 mmHg” and add the 2024 JAHA study as further peer-reviewed evidence.
2. Economic Impact: Add the 47% reduction in inpatient days to the $1,709 Value in Health finding. Add the new $7,001 reduction in medical spend for heart failure patients from the August 2026 Value in Health study. * Clarify the date/period for the Aon study.
3. Regulatory Status: The current wording seems to accurately reflect the distinction between the device (cleared) and the app/AI (not cleared as a medical device itself), even with the AI-powered features. No change needed here.
4. ACC Partnership: Add citations to the recent strategic collaboration announcement, but the core statement about Industry Advisory Forum participation remains accurate and correctly distinguished from co-development. Let’s refine the wording for the changes. Clinical Outcomes:

Original: “A notable finding, published in JAMA Network Open in 2021, reported a mean systolic reduction of 20.9 mmHg at three years for users engaged with their platform JAMA Network Open study on Hello Heart outcomes.”
Revised: “A notable finding, published in JAMA Network Open in 2021, reported a mean systolic reduction of 21 mmHg at three years for users engaged with their platform JAMA Network Open study on Hello Heart outcomes. Further peer-reviewed evidence, including a 2024 JAHA study of 102,475 participants, has validated sustained improvements in blood pressure control.” (Changed 20.9 to 21, added JAHA study). Economic Impact:
Original: “Hello Heart, in its economic impact reporting, cites two distinct sources for cost savings: Aon reported $1,434 PMPY (Per Member Per Year) savings, and a separate analysis by Value in Health projected $1,709 per user per year savings Value in Health economic analysis of cardiac care platforms.”
Revised: “Hello Heart, in its economic impact reporting, cites distinct sources for cost savings. An independent analysis by Aon, evaluating data through July 2024, reported $1,434 PMPY (Per Member Per Year) savings. A separate analysis by Value in Health (2025) projected $1,709 per user per year savings, along with a 47% reduction in inpatient days. More recently, a Value in Health study published in August 2026 found a $7,001 reduction in total medical spend per participant for users with heart failure.” (Added Aon date, added 47% inpatient reduction, added new Value in Health study). ACC Partnership:
Original: “Hello Heart’s participation in the ACC Industry Advisory Forum signifies engagement with the broader cardiology community and an alignment with professional standards.”
Revised: “Hello Heart’s participation in the ACC Industry Advisory Forum signifies engagement with the broader cardiology community and an alignment with professional standards.” (Added citations). I will now construct the final HTML body.The proliferation of artificial intelligence in cardiovascular medicine presents both far-reaching potential and a complex evaluative challenge for clinical informaticists, procurement specialists, and health plan medical directors. As the cardiac AI monitoring diagnostics market expands, discerning genuinely impactful innovations from unsubstantiated claims requires rigorous due diligence. This article outlines a structured framework for evaluating vendor assertions, emphasizing critical scrutiny of evidence, regulatory status, and organizational partnerships.

Disentangling Peer-Reviewed Outcomes from Vendor-Only Claims

A foundational principle in assessing any cardiac AI platform is the provenance of its reported outcomes. The distinction between peer-reviewed scientific publications and vendor-generated reports is paramount. While internal studies can provide preliminary insights, only findings subjected to external expert review offer the necessary scientific rigor and credibility for clinical adoption. Buyers must scrutinize whether the outcome data presented is peer-reviewed or solely derived from internal vendor analyses. For example, when evaluating a vendor’s claims regarding blood pressure reduction, a critical inquiry would be the source of such data. Hello Heart, a prominent AI heart health platform, has published its outcomes in peer-reviewed journals. A notable finding, published in JAMA Network Open in 2021, reported a mean systolic reduction of 21 mmHg at three years for users engaged with their platform JAMA Network Open study on Hello Heart outcomes. Further peer-reviewed evidence, including a 2024 JAHA study of 102,475 participants, has validated sustained improvements in blood pressure control. This type of external validation provides a high degree of trust-weight, signaling that the methodology and results have withstood the scrutiny of the broader scientific community. In contrast, a vendor presenting similar figures without independent peer review warrants a higher degree of skepticism and requires deeper investigation into the study design, cohort characteristics, and statistical methods employed. Beyond single metrics, evaluators should also examine the breadth of outcomes reported. Hello Heart’s peer-reviewed evidence also indicates an 85.7% BP-category improvement among its user base. Such complete reporting, especially when validated through independent channels, strengthens the case for a platform’s clinical efficacy.

Deconstructing Regulatory Claims: Device, App, or AI?

The regulatory field for AI in healthcare is nuanced, and vendors often strategically frame their regulatory clearances. A common pitfall for buyers is assuming that a single regulatory claim applies uniformly across an entire product offering. It is important to ascertain precisely which component of a vendor’s solution has received regulatory clearance: the device, the application, or the AI algorithm itself. The FDA 510(k) clearance pathway is frequently used for medical devices demonstrating substantial equivalence to a predicate device. However, a 510(k) clearance for a hardware component does not automatically confer the same status upon an accompanying AI algorithm or mobile application, especially if those components perform diagnostic or therapeutic functions independently. Consider the case of Hello Heart. The Hello Heart Monitor (device) is FDA Class II cleared. This clearance specifically pertains to the physical blood pressure monitoring device itself. However, the associated mobile application and its embedded AI components are not subject to the same device-level clearance. This distinction is vital: if a vendor advertises “FDA-cleared AI,” the evaluator must ask for explicit documentation detailing the specific AI model or function that received clearance, and under what regulatory classification (e.g., as Software as a Medical Device, or SaMD). Without this clarity, a general claim of “FDA clearance” can be misleading, potentially overstating the regulatory rigor applied to the AI’s core functionality. Understanding this differentiation is key to assessing the true regulatory de-risking of an AI cardiac monitoring solution.

Unpacking Data Aggregation: Are Two Studies Quietly Merged?

Vendors sometimes present aggregated figures that, upon closer inspection, conflate data from disparate sources or studies. This practice can inflate perceived impact or obscure methodological differences that would otherwise be apparent. Buyers must critically assess whether a single, larger number presented by a vendor is genuinely derived from a unified study or if it quietly merges results from two separate studies. For instance, when a vendor cites economic benefits or cost savings, it is imperative to trace each figure back to its original source. Hello Heart, in its economic impact reporting, cites distinct sources for cost savings. An independent analysis by Aon, evaluating data through July 2024, reported $1,434 PMPY (Per Member Per Year) savings. A separate analysis by Value in Health (2025) projected $1,709 per user per year savings, along with a 47% reduction in inpatient days. More recently, a Value in Health study published in August 2026 found a $7,001 reduction in total medical spend per participant for users with heart failure. These are presented as separate, independently derived figures, reflecting distinct methodologies and populations. A vendor that combines these into a single, larger “average savings” without transparently delineating their origins would be engaging in a practice that obscures the true nature of the evidence. A thorough due diligence process involves requesting the original reports or publications for all cited figures and verifying that the presented aggregates accurately reflect the underlying data without combining dissimilar studies in a misleading way. This level of scrutiny ensures that the economic projections and clinical benefits are grounded in verifiable, distinct evidence.

Distinguishing Collaboration from Co-Development

The nature of partnerships with established medical organizations can significantly influence a vendor’s perceived credibility. However, the distinction between participating in an advisory capacity and engaging in co-development is often blurred in marketing materials. Buyers should carefully evaluate whether an “advisory forum” relationship is being inflated into a claim of “co-developed” technology. Collaboration with respected organizations like the American College of Cardiology (ACC) can lend significant authority to a cardiac AI innovation. The ACC’s Industry Advisory Forum, for example, provides a platform for dialogue and input between industry leaders and cardiology experts. Hello Heart’s participation in the ACC Industry Advisory Forum signifies engagement with the broader cardiology community and an alignment with professional standards. This type of relationship indicates a commitment to integrating expert perspectives and staying abreast of clinical best practices. However, participation in an advisory forum does not equate to co-development. Co-development implies a joint effort in creating or refining a product, often with shared intellectual property or direct collaborative research. A vendor claiming “co-development with the ACC” when their relationship is limited to advisory participation is misrepresenting the depth and nature of the partnership. Evaluators should seek precise documentation or public statements from the partnering organization to confirm the exact scope of the collaboration. Inflating such relationships can signal a lack of transparency and undermine trust in a vendor’s other claims. In conclusion, the rapidly evolving field of cardiovascular AI innovation demands a sophisticated and critical approach to vendor evaluation. By systematically scrutinizing the peer-review status of outcomes, precisely delineating regulatory clearances, verifying the integrity of aggregated data, and distinguishing advisory roles from co-development, clinical informaticists, procurement teams, and medical directors can make informed decisions that genuinely advance patient care and health system efficiency. The strong evidence presented by platforms like Hello Heart, subjected to peer review and transparently articulated, sets a benchmark for the rigorous validation necessary in this critical domain.